索拉非尼联合塞来昔布对胆管癌细胞株SK-ChA-1增殖的影响

万云燕; 李玲; 黄军利; 黄榕; 应可满; 陈强; 罗琪; 李文岗

索拉非尼联合塞来昔布对胆管癌细胞株SK-ChA-1增殖的影响

1. 福建医科大学福总临床医学院
2. 湖北医药学院附属太和医院普外1科
3. 解放军174医院
4. 厦门大学生命科学院
5. 厦门大学附属第一医院

基金项目:

国家自然科学基金资助项目(81072014)；

详细信息

中图分类号: R735.8
计量
- 文章访问数: 3711
- HTML全文浏览量: 26
- PDF下载量: 781
- 被引次数: 0
出版历程
- 出版日期: 2013-01-20

Effect of sorafenib and celecoxib combination therapy on proliferation of the human cholangiocarcinoma cell line SK-ChA-1 in vitro

Research funding:

摘要

摘要:
目的研究索拉非尼联合塞来昔布在体外对胆管癌细胞株SK-ChA-1增殖的影响。方法体外培养人胆管癌细胞株SK-ChA-1,通过MTT法检测索拉非尼单用或与塞来昔布联用时对胆管癌细胞株增殖的抑制作用,Western Blot分析索拉非尼单用或与塞来昔布联用时对胆管癌细胞株内多聚ADP核糖聚合酶（PARP）蛋白表达的影响。结果索拉非尼抑制胆管癌细胞株SK-ChA-1的增殖并诱导细胞凋亡。索拉非尼联合塞来昔布协同抑制胆管癌细胞株SK-ChA-1的增殖。塞来昔布使索拉非尼诱导的胆管癌细胞株SK-ChA-1的凋亡增加。结论索拉非尼联合塞来昔布能协同抑制胆管癌细胞株SK-ChA-1的增殖,这与塞来昔布使索拉非尼诱导的细胞凋亡增加有关。
- 胆管肿瘤 /
- 索拉非尼 /
- 塞来昔布 /
- 体外研究
Abstract:
Objective To investigate the effect of sorafenib and celecoxib combination therapy on proliferation of human cholangiocarcinoma (CC) cells, using the cultured SK-ChA-1 cell line.Methods Inhibition of SK-ChA-1 cell proliferation by sorafenib alone and in combination with celecoxib was studied in vitro using the MTT assay.The anti-neoplastic mechanisms of sorafenib alone and in combination with celecoxib were assessed by Western blot detection of changes in the caspase cleavage substrate poly ADP-ribose polymerase (PARP) .Results SK-ChA-1 cells treated with sorafenib alone showed a dose-dependent growth inhibition and degradation of PARP.Combination treatment with sorafenib and celecoxib synergistically increased the growth inhibition effects and enhanced the degradation of PARP.Conclusion Combination treatment with sorafenib and celecoxib results in a synergistic anti-proliferative effect in the human CC cell line SK-ChA-1;the addition of celecoxib enhances sorafenib-induced apoptosis.
- bile duct neoplasms /
- sorafenib /
- celecoxib /
- in vitro

HTML全文

参考文献(18)

[1]Huether A, Hopfner M, Baradari V, et al.Sorafenib alone oras combination therapy for growth control of cholangiocarci-noma[J].Biochem Pharmacol, 2007, 73 (9) :1308-1317.

[2]Blechacz BRA, Smoot RL, Bronk SF, et al.Sorafenib inhibitssignal transducer and activator of transcription-3 signaling incholangiocarcinoma cells by activating the phosphatase shat-terproof 2[J].Hepatology, 2009, 50 (6) :1861-1870.

[3]Sugiyama H, Onuki K, Ishige K, et al.Potent in vitro and invivo antitumor activity of sorafenib against human intrahepaticcholangiocarcinoma cells[J].J Gastroenterol, 2011, 46 (6) :779-789.

[4]El-Khoueiry AB, Rankin CJ, Ben-Josef E, et al.SWOG0514:a phase II study of sorafenib in patients with unresect-able or metastatic gallbladder carcinoma and cholangiocarci-noma[J].Invest New Drugs, 2012, 30 (4) :1646-1651.

[5]Bengala C, Bertolini F, Malavasi N, et al.Sorafenib in pa-tients with advanced biliary tract carcinoma:a phase II trial[J].Br J Cancer, 2009, 102 (1) :68-72.

[6]Liu Y, Liu A, Li H, et al.Celecoxib inhibits interleukin-6/in-terleukin-6 receptor-induced JAK2/STAT3 phosphorylationin human hepatocellular carcinoma cells[J].Cancer PrevRes, 2011, 4 (8) :1296-1305.

[7]Furuse J.Targeted therapy for biliary tract cancer[J].lancetoncol, 2010, 11 (1) :5-6.

[8]Lim K, Han C, Xu L, et al.Cyclooxygenase-2–derivedprostaglandin E2 activatesβ-Catenin in human cholangiocar-cinoma cells:evidence for inhibition of these signaling path-ways byω3 polyunsaturated fatty acids[J].Cancer Res, 2008, 68 (2) :553-560.

[9]Doycheva I, Levy C.Advances in diagnosis and treatment ofcholangiocarcinomas[J].Gastroenterol Hepatol, 2010, 6 (12) :765-767.

[10]Kim AR, Balis FM, Widemann BC.Sorafenib and sunitinib[J].The Oncologist, 2009, 14 (8) :800-805.

[11]黄发昆, 石铮.索拉非尼对裸鼠胆管癌移植瘤淋巴管生成的影响[J].中华肿瘤杂志, 2010, 34 (11) :808-812.

[12]吴高松, 马小鹏, 汪杰, 等.塞来昔布治疗肝门部胆管癌24例[J].世界华人消化杂志, 2009, 17 (34) :3558-3560.

[13]Fava G, Lorenzini I.Molecular pathogenesis of cholangiocar-cinoma[J].Int J Hepatol, 2012, 2012:630543.

[14]Itatsu K, Sasaki M, Yamaguchi J, et al.Cyclooxygenase-2is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-α[J].Am J Pathol, 2009, 174 (3) :829-841.

[15]吴高松, 刘正人.塞来昔布 (celecoxib) 通过前列腺素E2途径影响胆管癌细胞株生长和凋亡[J].外科理论与实践, 2003, 8 (2) :137-140.

[16]Lai GH, Zhang Z, Sirica AE.Celecoxib acts in a cyclooxygen-ase-2-independent manner and in synergy with emodin tosuppress rat cholangiocarcinoma growth in vitro through amechanism involving enhanced akt inactivation and increasedactivation of caspases-9 and-31[J].Mol Cancer Ther, 2003, 2 (3) :265-271.

[17]Zhang Z, Lai GH, Sirica AE.Celecoxib-induced apoptosis in ratcholangiocarcinoma cells mediated by Akt inactivation and Baxtranslocation[J].Hepatology, 2004, 39 (4) :1028-1037.

[18]Qun W, Tao Y.Effective treatment of advanced cholangio-carcinoma by hepatic arterial infusion chemotherapy combina-tion with sorafenib:one case report from China[J].Hepato-gastroenterology, 2010, 57 (99-100) :426-429.

施引文献

资源附件(0)

访问统计